Table 1 The clinical information of patients recruited
From: Genetic variants in ADAM33 are associated with airway inflammation and lung function in COPD
| Â | CASE* | CONTROL |
|---|---|---|
Number of patients | 312 | 319 |
Age (years) | 60.5 (7.8) | 61.5 (8.1) |
Male: Female | 186:126 | 192:127 |
Pack years of smoking†| 35.46 (15.9) | 32.54 (12.7) |
FEV1 (% predicted)‡ | 52.5 (8.6) | 91.5 (9.6) |
FEV1/FVC (%)§ | 47.5 (7.6) | 90.5 (11.6) |
Postbd FEV1 (% predicted)|| | 58.5 (9.6) | 93.5 (10.5) |
Postbd FEV1/FVC (%) | 49.2 (8.5) | 91.5 (11.8) |
TLCO (% predicted)** | 63.09 (18.1) | 93.21 (2.9) |
GOLD status | Â | Â |
Stage I (mild) | 52 | - |
Stage II (moderate) | 140 | - |
Stage III (severe) | 98 | - |
Stage IV (very severe) | 22 | - |